What is TB-500?
TB-500 is a synthetic peptide derived from Thymosin Beta-4 (Tβ4), a protein that occurs naturally in almost all tissues and cells of the human body. Its active sequence (amino acids 17–23, LKKTETQ) is responsible for its effects on actin dynamics: it promotes the polymerization of G-actin into F-actin, which facilitates cell migration and proliferation in damaged tissues.
It was originally investigated in the context of cardiac healing following myocardial infarction, and subsequently in muscle, tendon, ligament, and skin repair.
Mechanism of action
TB-500 binds to G-actin (monomeric actin), regulating its availability for polymerization. This process is fundamental for:
- Cell migration: Cells need to reorganize their actin cytoskeleton to move toward the site of injury.
- Angiogenesis: Promotes the formation of new blood vessels in ischemic tissues.
- Cell differentiation: In cardiac models, favors cardiomyocyte regeneration.
Unlike BPC-157, which acts primarily on VEGFR2 and nitric oxide pathways, TB-500 operates at the cytoskeletal level, making it complementary in combined protocols.
Research areas
Preclinical models have explored TB-500 for:
- Repair of muscle tears and soft tissue injuries
- Recovery from tendon and ligament injuries
- Cardiac protection and regeneration post-infarction
- Healing of chronic skin wounds
- Reduction of fibrosis in damaged tissues
Reconstitution (research reference)
With a 5 mg vial + 2.0 mL bacteriostatic water: 1 unit on a U-100 syringe ≈ 25 mcg.
Steps:
- Inject bacteriostatic water slowly along the wall of the vial (not directly onto the powder).
- Rotate gently until dissolved; do not shake.
- Refrigerate at 2–8 °C once reconstituted; use within 28 days.
Safety notes
Preclinical studies have not reported significant toxicity. Adverse effects observed in reported use include: transient post-injection fatigue, mild dizziness, and injection site irritation. No large-scale controlled human data exist. Always consult a healthcare professional before initiating any protocol.
For research use only. This content is educational. TB-500 is not approved for the diagnosis, treatment, or prevention of any disease in humans.
Reported protocol (research reference)
| Vial sizes | 5 mg, 10 mg |
|---|---|
| Reported dose | Literature reports ranges of 2,000–2,500 mcg twice per week for 4–6 weeks of loading, followed by 200–300 mcg weekly maintenance. Reference values, not a usage indication. |
| Half-life | Approximately 30 minutes in plasma; tissue effects extend for hours. |
| FDA status | Not FDA approved |